Based on the Ionis Pharmaceuticals Inc stock forecast from 16 analysts, the average analyst target price for Ionis Pharmaceuticals Inc is USD 59.45 over the next 12 months. Ionis Pharmaceuticals Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Ionis Pharmaceuticals Inc is Slightly Bearish, which is based on 5 positive signals and 9 negative signals. At the last closing, Ionis Pharmaceuticals Inc’s stock price was USD 38.46. Ionis Pharmaceuticals Inc’s stock price has changed by +0.18% over the past week, +1.58% over the past month and -19.39% over the last year.
No recent analyst target price found for Ionis Pharmaceuticals Inc
No recent average analyst rating found for Ionis Pharmaceuticals Inc
Company Overview Ionis Pharmaceuticals Inc
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California. Read Less
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by heredita...Read More
Frequently Asked Questions About Ionis Pharmaceuticals Inc (IONS) Stock
Based on ratings from 16 analysts Ionis Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 13 buy, 1 sell and 6 hold ratings.
Unfortunately we do not have enough data on IONS's stock to indicate if its a good dividend stock.
Based on targets from 16 analysts, the average taret price for IONS is USD 59.45 over the next 12 months. The maximum analyst target price is USD 75 while the minimum anlayst target price is USD 37.
IONS stock's Price/Earning ratio is 524.14.
Our analysis grades IONS stock's Price / Earning ratio at F. This means that IONS stock's Price/Earning ratio is above 97% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this IONS may be a overvalued for its sector.
The last closing price of IONS's stock was USD 38.46.
The most recent market capitalization for IONS is USD 6.11B.
Based on targets from 16 analysts, the average taret price for IONS is projected at USD 59.45 over the next 12 months.
This means that IONS's stock price may go up by +54.58% over the next 12 months.
We can't find any ETFs which contains Ionis Pharmaceuticals Inc's stock.
As per our most recent records Ionis Pharmaceuticals Inc has 927 Employees.
Ionis Pharmaceuticals Inc's registered address is 2855 Gazelle Court, Carlsbad, CA, United States, 92010.
You can get more information about it from Ionis Pharmaceuticals Inc's website at https://www.ionispharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Frequently Asked Questions About Ionis Pharmaceuticals Inc (IONS) Stock
Based on ratings from 16 analysts Ionis Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 13 buy, 1 sell and 6 hold ratings.
Unfortunately we do not have enough data on IONS's stock to indicate if its a good dividend stock.
Based on targets from 16 analysts, the average taret price for IONS is USD 59.45 over the next 12 months. The maximum analyst target price is USD 75 while the minimum anlayst target price is USD 37.
IONS stock's Price/Earning ratio is 524.14.
Our analysis grades IONS stock's Price / Earning ratio at F. This means that IONS stock's Price/Earning ratio is above 97% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this IONS may be a overvalued for its sector.
The last closing price of IONS's stock was USD 38.46.
The most recent market capitalization for IONS is USD 6.11B.
Based on targets from 16 analysts, the average taret price for IONS is projected at USD 59.45 over the next 12 months.
This means that IONS's stock price may go up by +54.58% over the next 12 months.
We can't find any ETFs which contains Ionis Pharmaceuticals Inc's stock.
As per our most recent records Ionis Pharmaceuticals Inc has 927 Employees.
Ionis Pharmaceuticals Inc's registered address is 2855 Gazelle Court, Carlsbad, CA, United States, 92010.
You can get more information about it from Ionis Pharmaceuticals Inc's website at https://www.ionispharma.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for IONS !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
